- Home
- AAME vs LUNG Comparison
AAME vs LUNG Comparison
Compare AAME & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAME
- LUNG
- Stock Information
- Founded
- AAME 1968
- LUNG 1995
- Country
- AAME United States
- LUNG United States
- Employees
- AAME N/A
- LUNG N/A
- Industry
- AAME Life Insurance
- LUNG Industrial Specialties
- Sector
- AAME Finance
- LUNG Health Care
- Exchange
- AAME Nasdaq
- LUNG Nasdaq
- Market Cap
- AAME 56.6M
- LUNG 63.6M
- IPO Year
- AAME N/A
- LUNG 2020
- Fundamental
- Price
- AAME $2.87
- LUNG $1.92
- Analyst Decision
- AAME
- LUNG Buy
- Analyst Count
- AAME 0
- LUNG 7
- Target Price
- AAME N/A
- LUNG $6.81
- AVG Volume (30 Days)
- AAME 20.8K
- LUNG 5.8M
- Earning Date
- AAME 11-10-2025
- LUNG 10-29-2025
- Dividend Yield
- AAME 0.68%
- LUNG N/A
- EPS Growth
- AAME N/A
- LUNG N/A
- EPS
- AAME 0.10
- LUNG N/A
- Revenue
- AAME $198,977,000.00
- LUNG $90,549,000.00
- Revenue This Year
- AAME N/A
- LUNG $10.30
- Revenue Next Year
- AAME N/A
- LUNG $14.72
- P/E Ratio
- AAME $28.88
- LUNG N/A
- Revenue Growth
- AAME 6.98
- LUNG 18.24
- 52 Week Low
- AAME $1.25
- LUNG $1.47
- 52 Week High
- AAME $3.71
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- AAME 45.86
- LUNG 63.63
- Support Level
- AAME $2.92
- LUNG $1.56
- Resistance Level
- AAME $3.16
- LUNG $2.89
- Average True Range (ATR)
- AAME 0.14
- LUNG 0.16
- MACD
- AAME 0.01
- LUNG 0.04
- Stochastic Oscillator
- AAME 46.47
- LUNG 35.04
About AAME Atlantic American Corporation
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.